We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

57 hedge funds and large institutions have $23.4M invested in CTI BioPharma Corp. (DE) Common Stock in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

177% more call options, than puts

Call options by funds: $169K | Put options by funds: $61K

15% less funds holding

Funds holding: 67 → 57 (-10)

21% less capital invested

Capital invested by funds: $29.7M → $23.4M (-$6.24M)

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

58% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 19

Holders
57
Holders Change
-10
Holders Change %
-14.93%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
8
Reduced
19
Closed
16
Calls
$169K
Puts
$61K
Net Calls
+$108K
Net Calls Change
+$121K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$637K
2
Goldman Sachs
Goldman Sachs
New York
+$350K
3
Renaissance Technologies
Renaissance Technologies
New York
+$290K
4
PP
Paloma Partners
Connecticut
+$212K
5
Bank of America
Bank of America
North Carolina
+$192K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.27M
2
State Street
State Street
Massachusetts
-$868K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$414K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$212K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$161K

CTIC Hedge Fund Activity: Q2 2019 in Review

57 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q2 2019, worth a combined $23.4M — down 21% from $29.7M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of CTIC and 9 opened new positions — a net loss of 7 holders — while 19 trimmed existing stakes and 8 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $637K. The largest seller was BlackRock, cutting an estimated $2.27M.

  • 57 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q2 2019, down from 67 in Q1 2019.
  • Funds reported $23.4M of CTI BioPharma Corp. (DE) Common Stock stock for Q2 2019, down 21% quarter-over-quarter.
  • 9 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q2 2019 and 16 closed out, a net change of -7 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q2 2019 was Millennium Management, an estimated $637K added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q2 2019 was BlackRock, an estimated $2.27M sold.

Based on aggregated 13F filings for Q2 2019.